Tuesday, January 10, 2023 Daily Archives

Tides in! Deals and manufacturing news from Lilly, Merck, Cordenpharma, and more

by

BioProcess Insider turns the tides with news from Eli Lilly and Merck & Co., CordenPharma, and Aurisco in this oligonucleotide and peptide round-up. First up, and PeptiDream has garnered Big Pharma attention over the past couple of weeks, with both Eli Lilly and Merck & Co. (known as MSD outside north America) inking separate deals with the Japanese firm on the same day. PeptiDream uses its Peptide Discovery Platform System (PDPS) technology to produce highly diverse non-standard peptide libraries for…

January 10, 2023

WuXi Bio signs $1.5bn TCE antibody pact with GSK

by

WuXi Biologics has out-licensed global rights for up to four preclinical bi- and multi-specific TCE antibodies to GSK in a $1.5 billion agreement. TCEs are antibody-based immunotherapies that redirect T cells to kill cancer cells. Initially, GSK will have the rights to a preclinical bispecific antibody that crosslinks tumor cells and T cells by targeting a tumor-associated antigen (TAA) on tumor cells and CD3 expression on T cells. GSK may exercise rights for up to three additional earlier-stage preclinical TCE antibodies.…

January 10, 2023

Astrea adds chromatography offering through Delta buy

by

Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for the biopharma space. The deal, of which financial details remain undisclosed, sees Astrea Bioseparations acquire Delta Precision. The firm says the acquisition will enable its product offering to include an entire range of chromatography columns for biomanufacturing. Astrea claims Delta’s products are recognized in the field for their wide range of applications, protein purification, vaccine production, drug development, and ease of use. A spokesperson for Astrea told BioProcess…

January 10, 2023